Question explored with the scientific record
Evidence for antidepressants
Antidepressants help some people with depression, but the evidence is weaker than most patients are told, and the trials that exist are designed to find benefit, not harm.
The evidence here is a patchwork. The largest real-world study, STAR*D, found that Phase III trial criteria select a healthier subset of patients who get better outcomes, meaning the published efficacy numbers overstate what happens in routine practice [2]. Remission rates in the "efficacy-like" sample were 34%, versus 25% in the broader group [2]. That gap matters: the people you see in ads are not the people you are.
Several trials show that combining antidepressants from the start can raise remission rates. One small RCT found that mirtazapine plus venlafaxine produced a 58% remission rate versus 25% for fluoxetine alone [1]. But these are short-term studies, mostly 6-8 weeks, and none compare the drug to a true placebo in a way that isolates the drug effect from natural recovery [1, 3, 7]. The placebo response itself is large: in one pooled analysis, 33% of placebo patients remitted [3].
The evidence for long-term benefit is thinner. A 2008 trial found that cognitive therapy and behavioral activation prevented relapse as well as continued medication, and both psychotherapies outperformed medication withdrawal [4, 5]. Another study of chronic depression found that patients who stopped antidepressants during inpatient psychotherapy improved just as much as those who stayed on them, with no difference at one-year follow-up [6].
| Comparison | Remission or response rate | Notes |
|---|---|---|
| Fluoxetine alone (RCT) | 25% remission [1] | 8-week trial |
| Mirtazapine + venlafaxine | 58% remission [1] | 8-week trial |
| STAR*D efficacy-like sample | 34% remission [2] | Real-world, 14 weeks |
| STAR*D broader sample | 25% remission [2] | Real-world, 14 weeks |
| Placebo (pooled analysis) | 33% remission [3] | 8-week trial |
| CBT vs continued medication | No difference in relapse [4] | 2-year follow-up |
The safety data here is almost entirely about acute side effects and drug interactions. One FAERS analysis found that SSRIs carry a strong signal for serotonin syndrome, especially when combined with other serotonergic drugs [9]. The risk of abnormal bleeding is real: a meta-analysis found an odds ratio of about 1.5 for gastrointestinal bleeding, and the number needed to harm was 80 for postpartum hemorrhage in women on serotonergic antidepressants [8]. No long-term safety study comparing treated to untreated patients appears in this retrieval.
My call: antidepressants produce a modest, short-term benefit over placebo for some people, but the evidence is built on short trials with healthy trial populations, and the long-term safety data is absent. The effect is real but smaller than advertised. Confidence: moderate.
Sources used 9
-
Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study
This study investigates the efficacy of combining different antidepressant medications from treatment initiation in patients with major depressive disorder, demonstrating that combination therapies significantly improve remission rates compared to monotherapy.
DOI: 10.1176/appi.ajp.2009.09020186 -
Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report
Using STAR*D data from 2,876 analyzable depressed outpatients, this study compares outcomes between an efficacy-like sample meeting Phase III trial criteria and a nonefficacy sample, finding that Phase III criteria select a non-representative subset with better outcomes, thus ch…
DOI: 10.1176/appi.ajp.2008.08071027 -
Does pretreatment anxiety predict response to either bupropion SR or sertraline?
A retrospective pooled analysis of two identical randomized 8-week trials comparing bupropion SR and sertraline (with placebo arms) in adults with recurrent major depressive disorder found that pretreatment anxiety did not predict differential antidepressant response nor disting…
DOI: 10.1016/s0165-0327(00)00250-0 -
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression.
This randomized follow-up trial compares enduring relapse/recurrence prevention after acute-phase treatment for major depression among prior exposure to behavioral activation (BA) or cognitive therapy (CT) versus continued antidepressant medication (ADM), finding that both BA an…
DOI: 10.1037/0022-006X.76.3.468 -
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression.
A randomized, multi-site relapse-prevention trial comparing prior behavioral activation, prior cognitive therapy, and continued antidepressant medication in adults with major depression, demonstrating enduring relapse/recurrence protection from psychotherapy comparable to or exc…
DOI: 10.1037/0022-006x.76.3.468 -
Comparing outcomes in chronic depression following inpatient psychotherapy for patients continuing versus discontinuing antidepressant medication
In a naturalistic 12-week inpatient treatment study of chronic depression, patients who continued versus discontinued antidepressant medication (ADM) during psychotherapy both showed significant symptom improvement with no meaningful difference between groups at treatment or at …
DOI: 10.1002/cpp.2561 -
Un estudio multicéntrico doble ciego controlado con placebo de sertralina en el tratamiento agudo y de continuación de la depresión mayor
Sertraline demonstrates superior efficacy to placebo in the acute treatment (6 weeks) of major depressive disorder in outpatients, with higher response rates and lower discontinuation due to inefficacy; continuation among acute responders shows persistent improvement more often …
DOI: 10.1017/s1134066500002769 -
Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding
This study reviews the association between serotonin reuptake inhibitors (SRIs) and the risk of abnormal bleeding, highlighting mechanisms, evidence from various studies, and implications for clinical practice.
DOI: 10.1016/j.psc.2016.04.010 -
Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System
A large pharmacoepidemiological analysis of the FDA Adverse Event Reporting System (FAERS) to quantify the risk of serotonin syndrome with selective serotonin reuptake inhibitors (SSRIs) and to assess how drug-drug interactions with other serotonergic medications and opioids mod…
DOI: 10.1159/000546109